Combining Whole-Brain Radiotherapy with GefitinibErlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
Joint Authors
Zheng, Mao-hua
Sun, Hong-tao
Xu, Ji-guang
Yang, Gang
Huo, Lei-ming
Zhang, Pan
Tian, Jin-hui
Yang, Ke-hu
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-02-24
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC).
Methods.
Databases including PubMed, EMBASE.com, Web of Science, and Cochrane Library were searched from inception to April 12, 2015.
Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included.
Literature selection, data extraction, and quality assessment were performed independently by two trained reviewers.
RevMan 5.3 software was used to analyze data.
Results.
A total of 7 trials involving 622 patients were included.
Compared with WBRT alone or WBRT plus chemotherapy, WBRT plus gefitinib/erlotinib could significantly improve response rate (OR = 2.16, 95% CI: 1.35–3.47; P = 0.001 ), remission rate of central nervous system (OR = 6.06, 95% CI: 2.57–14.29; P < 0.0001 ), disease control rate (OR = 3.34, 95% CI: 1.84–6.07; P < 0.0001 ), overall survival (HR = 0.72, 95% CI: 0.58–0.89; P = 0.002 ), and 1-year survival rate (OR = 2.43, 95% CI: 1.51–3.91; P = 0.0002 ).
In adverse events (III-IV), statistically significant differences were not found, except for rash (OR = 7.96, 95% CI: 2.02–31.34; P = 0.003 ) and myelosuppression (OR = 0.19, 95% CI: 0.07–0.51; P = 0.0010 ).
Conclusions.
WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC.
American Psychological Association (APA)
Zheng, Mao-hua& Sun, Hong-tao& Xu, Ji-guang& Yang, Gang& Huo, Lei-ming& Zhang, Pan…[et al.]. 2016. Combining Whole-Brain Radiotherapy with GefitinibErlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed Research International،Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1098221
Modern Language Association (MLA)
Zheng, Mao-hua…[et al.]. Combining Whole-Brain Radiotherapy with GefitinibErlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed Research International No. 2016 (2016), pp.1-9.
https://search.emarefa.net/detail/BIM-1098221
American Medical Association (AMA)
Zheng, Mao-hua& Sun, Hong-tao& Xu, Ji-guang& Yang, Gang& Huo, Lei-ming& Zhang, Pan…[et al.]. Combining Whole-Brain Radiotherapy with GefitinibErlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed Research International. 2016. Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1098221
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1098221